Calcium in PDB 5crd: Wild-Type Human Skeletal Calsequestrin
Protein crystallography data
The structure of Wild-Type Human Skeletal Calsequestrin, PDB code: 5crd
was solved by
K.M.Lewis,
L.A.Ronish,
C.Kang,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
43.89 /
2.08
|
Space group
|
C 2 2 21
|
Cell size a, b, c (Å), α, β, γ (°)
|
59.170,
145.132,
110.242,
90.00,
90.00,
90.00
|
R / Rfree (%)
|
18.9 /
21.7
|
Calcium Binding Sites:
The binding sites of Calcium atom in the Wild-Type Human Skeletal Calsequestrin
(pdb code 5crd). This binding sites where shown within
5.0 Angstroms radius around Calcium atom.
In total 4 binding sites of Calcium where determined in the
Wild-Type Human Skeletal Calsequestrin, PDB code: 5crd:
Jump to Calcium binding site number:
1;
2;
3;
4;
Calcium binding site 1 out
of 4 in 5crd
Go back to
Calcium Binding Sites List in 5crd
Calcium binding site 1 out
of 4 in the Wild-Type Human Skeletal Calsequestrin
Mono view
Stereo pair view
|
A full contact list of Calcium with other atoms in the Ca binding
site number 1 of Wild-Type Human Skeletal Calsequestrin within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Ca401
b:71.2
occ:1.00
|
OD2
|
A:ASP80
|
2.4
|
45.7
|
1.0
|
O
|
A:VAL18
|
2.4
|
32.3
|
1.0
|
OD1
|
A:ASN17
|
2.4
|
61.7
|
1.0
|
O
|
A:HOH555
|
2.5
|
46.9
|
1.0
|
O
|
A:LEU74
|
2.6
|
36.4
|
1.0
|
N
|
A:VAL18
|
3.2
|
32.4
|
1.0
|
C
|
A:VAL18
|
3.3
|
36.4
|
1.0
|
C
|
A:LEU74
|
3.5
|
36.2
|
1.0
|
CG
|
A:ASP80
|
3.5
|
55.4
|
1.0
|
CG
|
A:ASN17
|
3.5
|
67.6
|
1.0
|
C
|
A:ASN17
|
3.7
|
43.0
|
1.0
|
CA
|
A:VAL18
|
3.8
|
35.9
|
1.0
|
NZ
|
A:LYS79
|
3.8
|
54.8
|
1.0
|
CA
|
A:VAL75
|
3.8
|
32.6
|
1.0
|
N
|
A:ASP76
|
3.8
|
38.6
|
1.0
|
CA
|
A:ASN17
|
4.0
|
42.3
|
1.0
|
N
|
A:VAL75
|
4.0
|
34.2
|
1.0
|
OD1
|
A:ASP80
|
4.1
|
47.0
|
1.0
|
N
|
A:ASN19
|
4.3
|
37.4
|
1.0
|
CB
|
A:ASN17
|
4.3
|
58.8
|
1.0
|
C
|
A:VAL75
|
4.3
|
40.6
|
1.0
|
ND2
|
A:ASN17
|
4.4
|
71.1
|
1.0
|
O
|
A:ASN17
|
4.5
|
45.6
|
1.0
|
CB
|
A:VAL18
|
4.5
|
29.5
|
1.0
|
CE
|
A:LYS79
|
4.5
|
68.2
|
1.0
|
CB
|
A:LEU74
|
4.5
|
30.5
|
1.0
|
CB
|
A:ASP80
|
4.5
|
46.4
|
1.0
|
CA
|
A:LEU74
|
4.6
|
31.9
|
1.0
|
CA
|
A:ASN19
|
4.7
|
42.5
|
1.0
|
CB
|
A:ASP76
|
4.7
|
45.8
|
1.0
|
CB
|
A:ASN19
|
4.9
|
30.9
|
1.0
|
CA
|
A:ASP76
|
4.9
|
35.8
|
1.0
|
|
Calcium binding site 2 out
of 4 in 5crd
Go back to
Calcium Binding Sites List in 5crd
Calcium binding site 2 out
of 4 in the Wild-Type Human Skeletal Calsequestrin
Mono view
Stereo pair view
|
A full contact list of Calcium with other atoms in the Ca binding
site number 2 of Wild-Type Human Skeletal Calsequestrin within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Ca402
b:71.8
occ:1.00
|
O
|
A:HOH693
|
2.3
|
54.5
|
1.0
|
OG1
|
A:THR277
|
2.3
|
49.2
|
1.0
|
OE2
|
A:GLU199
|
2.4
|
35.9
|
1.0
|
OG1
|
A:THR229
|
2.5
|
29.0
|
1.0
|
OE1
|
A:GLU199
|
2.5
|
41.8
|
1.0
|
O
|
A:THR277
|
2.5
|
52.7
|
1.0
|
CD
|
A:GLU199
|
2.8
|
52.5
|
1.0
|
CA
|
A:THR277
|
3.3
|
42.6
|
1.0
|
C
|
A:THR277
|
3.3
|
49.3
|
1.0
|
CB
|
A:THR277
|
3.3
|
52.3
|
1.0
|
CB
|
A:THR229
|
3.6
|
30.5
|
1.0
|
N
|
A:THR229
|
4.0
|
27.5
|
1.0
|
O
|
A:HOH509
|
4.2
|
45.2
|
1.0
|
CG
|
A:GLU199
|
4.3
|
32.1
|
1.0
|
O
|
A:HOH621
|
4.3
|
56.9
|
1.0
|
O
|
A:HOH700
|
4.4
|
42.0
|
1.0
|
CA
|
A:THR229
|
4.4
|
31.7
|
1.0
|
CG2
|
A:THR277
|
4.4
|
48.3
|
1.0
|
N
|
A:GLU278
|
4.6
|
57.0
|
1.0
|
O
|
A:HOH593
|
4.6
|
47.0
|
1.0
|
CE
|
A:MET202
|
4.7
|
48.4
|
1.0
|
N
|
A:THR277
|
4.7
|
41.1
|
1.0
|
O
|
A:HOH556
|
4.7
|
30.4
|
1.0
|
CG2
|
A:THR229
|
4.8
|
33.3
|
1.0
|
|
Calcium binding site 3 out
of 4 in 5crd
Go back to
Calcium Binding Sites List in 5crd
Calcium binding site 3 out
of 4 in the Wild-Type Human Skeletal Calsequestrin
Mono view
Stereo pair view
|
A full contact list of Calcium with other atoms in the Ca binding
site number 3 of Wild-Type Human Skeletal Calsequestrin within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Ca403
b:78.3
occ:1.00
|
O
|
A:HOH503
|
2.1
|
59.6
|
1.0
|
O
|
A:ASP210
|
2.2
|
43.4
|
1.0
|
OE1
|
A:GLU217
|
2.4
|
45.8
|
1.0
|
O
|
A:PRO212
|
2.5
|
38.7
|
1.0
|
OE2
|
A:GLU217
|
2.7
|
64.0
|
1.0
|
O
|
A:HOH678
|
2.8
|
59.7
|
1.0
|
CD
|
A:GLU217
|
2.9
|
48.1
|
1.0
|
C
|
A:ASP210
|
3.5
|
34.8
|
1.0
|
C
|
A:PRO212
|
3.5
|
39.8
|
1.0
|
CB
|
A:ASP210
|
3.9
|
51.2
|
1.0
|
CA
|
A:ASN213
|
3.9
|
32.6
|
1.0
|
ND2
|
A:ASN213
|
4.1
|
33.0
|
1.0
|
N
|
A:ASN213
|
4.2
|
31.5
|
1.0
|
CA
|
A:ASP210
|
4.3
|
49.2
|
1.0
|
N
|
A:LYS211
|
4.4
|
31.9
|
1.0
|
CG
|
A:GLU217
|
4.4
|
45.6
|
1.0
|
C
|
A:LYS211
|
4.5
|
48.1
|
1.0
|
CA
|
A:LYS211
|
4.5
|
39.2
|
1.0
|
N
|
A:PRO212
|
4.5
|
40.7
|
1.0
|
N
|
A:SER214
|
4.5
|
28.4
|
1.0
|
CA
|
A:PRO212
|
4.7
|
35.6
|
1.0
|
C
|
A:ASN213
|
4.7
|
28.0
|
1.0
|
O
|
A:HOH710
|
4.8
|
45.1
|
1.0
|
CG
|
A:ASN213
|
4.9
|
29.9
|
1.0
|
O
|
A:LYS211
|
4.9
|
46.8
|
1.0
|
CB
|
A:ASN213
|
4.9
|
29.0
|
1.0
|
O
|
A:PRO209
|
5.0
|
38.0
|
1.0
|
|
Calcium binding site 4 out
of 4 in 5crd
Go back to
Calcium Binding Sites List in 5crd
Calcium binding site 4 out
of 4 in the Wild-Type Human Skeletal Calsequestrin
Mono view
Stereo pair view
|
A full contact list of Calcium with other atoms in the Ca binding
site number 4 of Wild-Type Human Skeletal Calsequestrin within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Ca404
b:86.0
occ:1.00
|
O
|
A:THR189
|
2.3
|
46.0
|
1.0
|
OG1
|
A:THR189
|
2.4
|
44.1
|
1.0
|
O
|
A:HOH630
|
2.5
|
42.2
|
1.0
|
CB
|
A:THR189
|
3.1
|
43.3
|
1.0
|
C
|
A:THR189
|
3.4
|
33.2
|
1.0
|
CA
|
A:THR189
|
3.8
|
32.5
|
1.0
|
O
|
A:HOH640
|
3.9
|
44.7
|
1.0
|
OD2
|
A:ASP196
|
4.0
|
36.5
|
1.0
|
O
|
A:LEU188
|
4.2
|
39.7
|
1.0
|
CG2
|
A:THR189
|
4.4
|
38.2
|
1.0
|
N
|
A:LEU190
|
4.5
|
38.4
|
1.0
|
OE1
|
A:GLU194
|
4.7
|
34.8
|
1.0
|
OD1
|
A:ASP196
|
4.8
|
31.7
|
1.0
|
CG
|
A:ASP196
|
4.8
|
41.4
|
1.0
|
N
|
A:THR189
|
4.9
|
37.3
|
1.0
|
CA
|
A:LEU190
|
5.0
|
34.0
|
1.0
|
C
|
A:LEU188
|
5.0
|
47.7
|
1.0
|
|
Reference:
K.M.Lewis,
L.A.Ronish,
E.Rios,
C.Kang.
Characterization of Two Human Skeletal Calsequestrin Mutants Implicated in Malignant Hyperthermia and Vacuolar Aggregate Myopathy. J.Biol.Chem. V. 290 28665 2015.
ISSN: ESSN 1083-351X
PubMed: 26416891
DOI: 10.1074/JBC.M115.686261
Page generated: Sun Jul 14 17:15:07 2024
|